Cargando…

Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

The treatment landscape in oncology has witnessed a major revolution with the introduction of checkpoint inhibitors: anti-PD1, anti-PDL1 and anti-CTLA-4. These agents enhance the immune response towards cancer cells instead of targeting the tumor itself, contrary to standard chemotherapy. Although l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haibe, Yolla, El Husseini, Ziad, El Sayed, Rola, Shamseddine, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504220/ https://www.ncbi.nlm.nih.gov/pubmed/32867025 http://dx.doi.org/10.3390/ijms21176176

Ejemplares similares

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
por: El Sayed, Rola, et al.
Publicado: (2021)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Management of colorectal cancer in the era of COVID-19: Challenges and suggestions
por: Alam, Walid, et al.
Publicado: (2021)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade
por: Abdel Sater, Ali H., et al.
Publicado: (2022)

Thrombotic Microangiopathy in the Setting of Colorectal Cancer: A Therapeutic Challenge with a Bad Prognosis
por: Bouferraa, Youssef, et al.
Publicado: (2023)

The unveiling of a new risk factor associated with bladder cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2019)

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges
por: Bouferraa, Youssef, et al.
Publicado: (2021)

The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study
por: Bouferraa, Youssef, et al.
Publicado: (2022)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

Mechanisms of resistance to immune checkpoint inhibitors
por: Jenkins, Russell W, et al.
Publicado: (2018)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

Mechanisms of resistance to immune checkpoint inhibitors
por: Nagasaki, Joji, et al.
Publicado: (2022)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020)

Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
por: Machmouchi, Ahmad, et al.
Publicado: (2023)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Female oncologists in the Middle East and North Africa: progress towards gender equality
por: Salem, Rana, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Immune checkpoint inhibitor resistance in soft tissue sarcoma
por: Eulo, Vanessa, et al.
Publicado: (2022)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
por: Tojjari, Alireza, et al.
Publicado: (2023)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
por: Wang, Bin, et al.
Publicado: (2023)

Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
por: Seto, Tiffany, et al.
Publicado: (2019)

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors
por: Samnani, Sunil, et al.
Publicado: (2023)

Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
por: El Sabbagh, Rawaa, et al.
Publicado: (2020)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
por: Qian, Fang-Fei, et al.
Publicado: (2020)

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
por: Li, Yinuo, et al.
Publicado: (2023)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
por: Boyero, Laura, et al.
Publicado: (2020)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
por: Baxter, Mark A., et al.
Publicado: (2021)

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
por: Sahin, Ibrahim Halil, et al.
Publicado: (2019)

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
por: El Sayed, Rola, et al.
Publicado: (2019)

A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
por: Kareva, Irina
Publicado: (2017)

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
por: Li, Shamin, et al.
Publicado: (2021)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_89s84sfgm9alcha8i4pvjl1te4